Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Articles

Survey results and record attendance show positive signs for various bio/pharma regions.

Innovation and Industry Strength Recognized at CPhI

Cambrex will create a new center of excellence for API process development and clinical supply at its High Point, NC facility and expand its API manufacturing facility in Italy. 

Cambrex Development Center in North Carolina Focuses on Continuous Flow

At CPhI Worldwide 2018, Tom Wilson, vice president of Contract Manufacturing Operations for Pfizer Global Supply and Pfizer CentreOne Contract Manufacturing, will discuss best practices for meeting manufacturing challenges of compliance as requirements shift.

Presentation on the Manufacture of Highly Potent Oral Solid-Dosage Forms

Funding from Innovate UK will be used by Medherant to support manufacture of transdermal patches for clinical trials.

Medherant Receives Grant from Innovate UK for Transdermal Patch Manufacturing

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Innovative technologies, such as drug-loaded devices and 3D printing, enable advances in implantable devices and other novel dosage forms.

New Dose Forms Focus on the Patient

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Lipid-based formulations offer a means of addressing the physicochemical and biological challenges of poorly soluble APIs.

Developing Lipid-Based Formulations

Vetter chose a winner from four teams that worked for three months to develop ideas for applying digital technology to injectable pharmaceuticals. 

Vetter Awards Winner of Open Innovation Challenge

3D printing is being explored as a manufacturing method for on-demand, personalized medicine.

Considering 3D Printing for Solid Dosage Forms

As it investigates the root cause of an impurity discovered in valsartan, FDA extends its studies to APIs with similar synthesis processes.

FDA Expands NDMA Investigation to All ARB Class Drugs

Senomyx uses an approach, known as taste-blocking, to address the challenges of bitter APIs. Kenneth J. Simone, vice-president of Pharmaceutical Business Development, Senomyx, speaks with Pharmaceutical Technology about this technology. 